Accelerate to discover

Back to filter

Related topics

Webinar: Join us for an In-Depth Look at the Revolutionary Small Animal Radiotherapy System at STTARR

Precision X-Ray

Aug 17, 2023

Register for an engaging webinar led by Naz Chaudary, Ph.D., and Research Technician, Alex Wang from the...

Optimizing Gene Expression with Bioluminescence & the piggyBac System

Spectral Instruments Imaging

Aug 15, 2023

Discover how bioluminescence imaging & the piggyBac gene editing system optimize & track gene expression in mouse...

High-plex immunofluorescence imaging and traditional histology of the same tissue section

RareCyte

Aug 7, 2023

RareCyte Orion’ platform has been used for collecting H&E and high-plex immunofluorescence images from the same cells...

Drive key insights and discoveries with NEW Live Cell Analysis applications for eSight system

Agilent technologies

Aug 2, 2023

eSight is now powerful like never before. Learn more about new dedicated application modules for live-cell analysis: 3D...

Sep 24, 2023

Single cell-resolution in situ sequencing elucidates spatial dynamics of multiple sclerosis

Vizgen

Jul 14, 2023

MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, fluidics, image processing,...

MARS - High Efficiency Separation of CD34+ HSC from Mobilized Blood

Applied Cells

Jul 12, 2023

MARS platform provides an easy and cost-effective protocol for CD34+ cell isolation. Single pass CD34+ HSC enrichment...

43 markers, ONE tube : Impress yourself with Cytek Aurora Spectral Cytometer

Cytek Biosciences

Jul 11, 2023

Using Cytek full spectrum flow cytometry, scientists at Hamad Medical Corporation, developed a 43 color panel to...

Sep 24, 2023

InAlyzer - The technology chosen by NASA

MEDIKORS

Jul 10, 2023

MEDIKORS's InAlyzer was finally selected as the equipment to be used for NASA's space environment biological research

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey